Pharmacogenetic monitoring of imantinib use in patientes with Chronic Myeloid Leukemia

• Autor(a) principal: Rivera, Juan Gonzalo Bardález
• Data de Publicação: 2023
• Outros Autores: Quemel, Gleicy Kelly China, Abrantes, Gisely France, Araújo, Alessandra Cuimar, Cardoso, João Laudelino Cardoso, Campos, Marcelo Franças Fernandes
• Tipo de documento: Artigo
• Idioma: por
• Título da fonte: Revista JRG de Estudos Acadêmicos
• Texto Completo: http://revistajrg.com/index.php/jrg/article/view/714
• topic: Leucemia mieloíde crônica. Imantinibe. Farmacogenética; Chronic myeloid leukemia. Imantinib. Pharmacogenetics

Chronic Myeloid Leukemia (CML) is a malignant myeloproliferative neoplasm that accounts for 20% of all leukemias. In 90-95% of cases, this neoplasm is associated with the presence of the Philadelphia chromosome. Imatinib has been confirmed as a first-line therapy for the pharmacological treatment of CML because it has long-lasting responses in most patients, especially those in the chronic phase of the disease; however, some patients still in the chronic phase and a greater proportion in more advanced phases of CML present resistance or intolerance to imatinib, due to the therapeutic dose and the appearance of toxic effects. Another finding is related to the pharmacogenetic profile of the patients, which makes the treatment personalized. The general objective of this article is to carry out an integrative literature review regarding the pharmacogenetic monitoring of imatinib in patients with Chronic Myeloid Leukemia. Thirteen articles were found in the online databases, which met the inclusion and exclusion criteria of the research. It is concluded that the study of the pharmacogenetics of imatinib has been the subject of many recent studies. Therefore, its understanding can help to personalize the pharmacological treatment of the same and to improve the effectiveness of the drug in patients with CML and to minimize the appearance of adverse reactions and failures in the drug therapy.